Inventiva S.A. (IVA)Healthcare | Biotechnology | Daix, France | NasdaqGM
4.30 USD
After hours: 4.38 +0.08 (1.860%) ⇧ (July 13, 2026, 7:53 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:12 a.m. EDT
The investment case here is defined by a stark disconnect between aggressive analyst optimism and deteriorating corporate reality. While analysts project a mean target price significantly higher than the current level, the company's fundamentals tell a story of contraction and distress. Revenue has plummeted by nearly 90% year-over-year, operating margins are deeply negative, and the company is burning through cash with no free cash flow generation. The balance sheet is fragile, with debt exceeding cash reserves and negative book value, indicating that the equity has little intrinsic cushion. The price action reflects this uncertainty. Although there was a recent bounce, the stock remains well below its 200-day average, and the multi-year trajectory shows a catastrophic loss of value. The recent recovery in the latest annual anchor suggests a temporary stabilization, but it does not erase the structural damage caused by the previous years of decline. With no dividend to provide income and a business model currently failing to generate revenue or profit, the risk of permanent capital impairment is high. The speculative options activity hints at a desire for a turnaround, but without evidence of commercialization success or a path to profitability, this remains a high-risk gamble rather than a sound investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.165920 |
| AutoTheta | 0.174667 |
| AutoARIMA | 0.185243 |
| MSTL | 0.190633 |
| MSTL_105 | 0.277723 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 44.36 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.046 |
| Excess Kurtosis | -1.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.036 |
| Market Cap | 1,015,748,864 |
| Forward P/E | -4.90 |
| Beta | 0.89 |
| Website | https://inventivapharma.com |
As of July 11, 2026, 5:12 a.m. EDT: Speculator positioning is extremely thin and fragmented, offering little clarity on immediate direction. There is a notable concentration of out-of-the-money call open interest at the $5.00 strike for August expiration, suggesting a speculative hope for a move above current levels. However, this is offset by significant put open interest at the $2.50 strike for July expiration, acting as a floor or insurance against further downside. The lack of volume in most strikes indicates these positions are static rather than actively driven by fresh capital flow.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2427746 |
| Address1 | 50 rue de Dijon |
| All Time High | 19.064 |
| All Time Low | 1.53 |
| Ask | 4.31 |
| Ask Size | 4 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,023,690 |
| Average Daily Volume3 Month | 852,836 |
| Average Volume | 852,836 |
| Average Volume10Days | 2,023,690 |
| Beta | 0.892 |
| Bid | 4.29 |
| Bid Size | 1 |
| Book Value | -0.16925871 |
| City | Daix |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.3 |
| Current Ratio | 3.159 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.51 |
| Day Low | 4.205 |
| Display Name | Inventiva |
| Earnings Call Timestamp End | 1,774,987,200 |
| Earnings Call Timestamp Start | 1,774,987,200 |
| Earnings Timestamp End | 1,774,900,800 |
| Earnings Timestamp Start | 1,774,900,800 |
| Ebitda | -132,497,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.73 |
| Enterprise To Revenue | 151.485 |
| Enterprise Value | 1,024,193,152 |
| Eps Current Year | -0.80117 |
| Eps Forward | -0.87833 |
| Eps Trailing Twelve Months | -2.16 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4986 |
| Fifty Day Average Change | -0.19859982 |
| Fifty Day Average Change Percent | -0.044147026 |
| Fifty Two Week Change Percent | 24.27746 |
| Fifty Two Week High | 7.983 |
| Fifty Two Week High Change | -3.6829996 |
| Fifty Two Week High Change Percent | -0.46135533 |
| Fifty Two Week Low | 2.854 |
| Fifty Two Week Low Change | 1.4460001 |
| Fifty Two Week Low Change Percent | 0.50665736 |
| Fifty Two Week Range | 2.854 - 7.983 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,594,387,800,000 |
| Float Shares | 160,692,888 |
| Forward Eps | -0.87833 |
| Forward P E | -4.8956547 |
| Free Cashflow | -200,711,632 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.99675006 |
| Gross Profits | 6,739,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.2608 |
| Implied Shares Outstanding | 236,220,651 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-10 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. |
| Long Name | Inventiva S.A. |
| Market | us_market |
| Market Cap | 1,015,748,864 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_273516426 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -354,137,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,003,460,709 |
| Number Of Analyst Opinions | 13 |
| Open | 4.31 |
| Operating Cashflow | -104,884,000 |
| Operating Margins | -67.10686 |
| Payout Ratio | 0.0 |
| Phone | 33 3 80 44 75 00 |
| Post Market Change | 0.07999992 |
| Post Market Change Percent | 1.8604633 |
| Post Market Price | 4.38 |
| Post Market Time | 1,783,986,809 |
| Previous Close | 4.3 |
| Price Eps Current Year | -5.367151 |
| Price Hint | 4 |
| Price To Book | -25.404898 |
| Price To Sales Trailing12 Months | 150.23648 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.408 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.15385 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 4.51 |
| Regular Market Day Low | 4.205 |
| Regular Market Day Range | 4.205 - 4.51 |
| Regular Market Open | 4.31 |
| Regular Market Previous Close | 4.3 |
| Regular Market Price | 4.3 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 733,953 |
| Return On Assets | -0.45079 |
| Revenue Growth | -0.899 |
| Revenue Per Share | 0.036 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 236,220,651 |
| Shares Percent Shares Out | 0.006 |
| Shares Short | 1,424,175 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 688,163 |
| Short Name | Inventiva S.A. - American Depos |
| Short Percent Of Float | 0.0064 |
| Short Ratio | 1.12 |
| Source Interval | 15 |
| Symbol | IVA |
| Target High Price | 26.0 |
| Target Low Price | 8.8 |
| Target Mean Price | 15.12577 |
| Target Median Price | 13.0 |
| Total Cash | 99,839,000 |
| Total Cash Per Share | 0.481 |
| Total Debt | 230,890,000 |
| Total Revenue | 6,761,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.1571 |
| Two Hundred Day Average Change | -0.8571 |
| Two Hundred Day Average Change Percent | -0.16619806 |
| Type Disp | Equity |
| Volume | 733,953 |
| Website | https://inventivapharma.com |
| Zip | 21,121 |